Clinical Trial Update: Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the CAMP regimen—chidamide in combination with azacitidine, liposomal mitoxantrone, and prednisone—for previously untreat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Helper Cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Chidamide (chidamide)
• Liposomal mitoxantrone (mitoxantrone)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Peripheral T Cell Lymphoma, Epigenetic Repression | Phase 2 | Status: RECRUITING